GTx, Inc. (NASDAQ:GTXI) insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $35,009.70. Following the completion of the sale, the insider now directly owns 31,111 shares of the company’s stock, valued at $352,487.63. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of GTx, Inc. (GTXI) traded down $0.22 during mid-day trading on Friday, hitting $14.31. 48,443 shares of the company were exchanged, compared to its average volume of 76,833. The stock has a market cap of $308.26, a PE ratio of -8.18 and a beta of 1.78. GTx, Inc. has a 12 month low of $2.73 and a 12 month high of $15.81.
GTX (NASDAQ:GTXI) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.25). equities research analysts forecast that GTx, Inc. will post -1.61 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in shares of GTX during the 2nd quarter valued at approximately $124,000. Caxton Corp purchased a new stake in shares of GTX during the 3rd quarter valued at approximately $531,000. Finally, Abingworth LLP purchased a new stake in GTX in the 3rd quarter worth approximately $2,781,000. Institutional investors own 11.57% of the company’s stock.
A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of GTX from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Zacks Investment Research cut shares of GTX from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Robert W. Baird assumed coverage on shares of GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of GTX in a research note on Thursday, November 9th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.00.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/02/jason-t-shackelford-sells-3090-shares-of-gtx-inc-gtxi-stock.html.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.